EUCTR2011-004764-30-FR进行中（未招募）1 期
Phase 2 study of a reduced-toxicity myeloablative conditionning regimen using fludarabine and full doses of IV busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens. - FB4-PEDIA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- CHU Nantes
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Children and adolescents under the age of 18 years
- •- Availability of an HLA identical family donor or an HLA-matched unrelated donor (10/10 or 9/10 if the mismatch level is at HLACw for an unrelated donor)
- •- Informed consent signed by patient’s legal representative, parent(s) or guardian.
- •- Diagnosis of a hematologic malignancy which is a candidate for allo-HSCT, but not eligible for standard or conventional myeloablative conditioning regimens because of high risk for toxicity.
- •- Are considered as criteria of eligibility for non-standard or conventional myeloablative conditioning:
- •* a history of autologous or allogeneic stem cell transplantation
- •* comorbidities or medical history predictive of a prohibitive rate of TRM and toxicity with the use of standard high dose chemotherapy and / or radiotherapy.
- •- Eligible hematologic malignancies treatable with allogeneic hematopoietic cell transplantation include: acute and chronic leukemias, myelodysplasia [MDS], or lymphomas.
- •? Patients with ALL are required to be in morphologic remission (<5%blasts), whereas patients with acute myelogenous leukemia (AML) not in stringent CR are allowed (Patients not in CR should be discussed with the PI on a case per case basis).
- •? Patients with juvenile myelomonocytic leukemia (JMML) and MDS are required to have less than 5% blasts, and those with chronic myelogenous leukemia have to be in first chronic phase, accelerated phase, or subsequent chronic phase with less than 5% blasts.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 50
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patient has been administered any other systemic chemotherapeutic drug (including Gemtuzumab) within 21 days prior to trial enrollment and start of the conditioning regimen. Hydroxyurea is permitted if indicated to control induction refractory disease, and IT chemotherapy is allowed if indicated as maintenance treatment for previously diagnosed leptomeningeal disease, that has been in remission for at least 3 months prior to enrollment on this study.
- •- Active infection. Protocol PI will be final arbiter if there is uncertainty regarding whether a previous infection is resolved.
- •- Age =18 years
- •- A donor who is HLA mismatched at the level of more than one locus.
- •- Poor performance status
- •- Life expectancy is severely limited by concomitant illness and expected to be <12 weeks.
- •- Left ventricular ejection fraction <30%. Uncontrolled arrhythmias or symptomatic cardiac disease.
- •- Symptomatic pulmonary disease. FEV1, FVC and DLCO <30% of expected corrected for hemoglobin.
- •- Creatinine clearance less than 30 mL/m per 1.73 m2 or requiring dialysis
- •- Evidence of chronic active hepatitis or cirrhosis. If positive hepatitis serology, discuss with Study Chairman and consider liver biopsy.
- •- Effusion or ascites >1L prior to drainage.
- •- HIV-positive.
- •- Female pregnancy (all females of child-bearing-potential).
- •- Patient’s legal representative, parent(s) or guardian not able to sign informed consent.
研究者
相似试验
已完成
2 期
Randomized phase II study using a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2 in metastatic melanomaskin cancermalignant melanoma10040900NL-OMON34085ederlands Kanker Instituut45
进行中（未招募）
1 期
Randomized Phase II Study Using a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 in Metastatic Melanoma’ - Lymphodepletion, TIL and Interleukin 2Patients with metastatic (stage IV) melanoma will be randomized to either treatment arm A (dacarbazine) or treatment arm B (TIL) after metastasectomy and feasibility of culturing of TIL.MedDRA version: 12.1Level: LLTClassification code 10053571Term: MelanomaEUCTR2010-021885-31-NLKI-AV
已完成
2 期
Treosulfan-based Conditioning in Paediatric Patients With Haematological MalignanciesAcute Lymphoblastic Leukaemias (ALL)Acute Myeloid Leukaemias (AML)Myelodysplastic Syndromes (MDS)Juvenile Myelomonocytic Leukaemias (JMML)NCT02333058medac GmbH70
进行中（未招募）
1 期
Phase II prospective study on high dose myeloablative therapy, with peripheral stem cell support, in elderly patients (>=65 e <76 years) with aggressive relapsed or refractory non Hodgkin lymphoma - NDEUCTR2009-015974-36-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
进行中（未招募）
2 期
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersMesotheliomaNeuroendocrine TumorsSquamous Cell CancerMismatch Repair DeficiencyMicrosatellite InstabilityColorectal CancerPancreatic CancerGastric CancerSarcomaMerkel Cell CarcinomaNCT03935893Udai Kammula20